NICE recommends darolutamide with androgen deprivation therapy and docetaxel for patients with hormone-sensitive metastatic prostate cancer

The National Institute for Health and Clinical Excellence (NICE) has now issued its final guidance recommending the use of darolutamide with androgen deprivation therapy (ADT) and docetaxel on the NHS for patients with hormone-sensitive metastatic prostate cancer.

The National Institute for Health and Clinical Excellence (NICE) has issued draft guidance (18 May 2023) recommending the use of darolutamide with androgen deprivation therapy (ADT) and docetaxel on the NHS for patients with hormone-sensitive metastatic prostate cancer.

Darolutamide (also called Nubeqa®) is a type of hormone therapy which blocks the action of testosterone on prostate cancer cells. It has previously been available for patients whose prostate cancer is no longer responding to other types of hormone therapy and has not spread. Clinical trials have shown that combining darolutamide with ADT and docetaxel leads to improved survival for men whose prostate cancer is still responding to hormone therapy and has spread to other parts of the body.